Recent news on Rituxan

New drug improves long term survival for mantle cell lymphoma  -  May 22, 2007
TopCancerNews.com,The Journal of Clinical Oncology found that by adding Rituxan(rituximab) to the MCP combination, the long time survival rates are improved.

Promising new treatments for cancer and osteoporosis.  -  May 22, 2007
SlateAs the drug Rituxan, which consists of the antibody without the radioactivity, they are already widely used for non-Hodgkin's lymphoma and other cancers.

Rituxan Phase II Data in Patients with Relapsing-Remitting ...  -  May 2, 2007
PipelineReview.com (press release),In this Phase II double-blind, placebo-controlled study that evaluated the safety and efficacy of Rituxan in adult patients with RRMS, 104 patients were

Rituxan shows promise in multiple sclerosis trial  -  May 1, 2007
Reuters AlertNet,NEW YORK, May 1 (Reuters) - Genentech Inc. and Biogen Idec Inc. said on Tuesday their Rituxan cancer drug proved highly effective against multiple sclerosis

Dr Reddy's launches Rituxan biosimilar in India  -  May 3, 2007
LabTechnologist.com,03/05/2007 - Indian drug maker Dr Reddy's has launched a generic version of Roche's biologic blockbuster Rituxan in India, in a move that fuels further the

Rituxan shows promise in multiple sclerosis trial  -  May 1, 2007
ReutersO: Quote, Profile, Research said on Tuesday their blockbuster Rituxan drug for lymph cancer was highly effective against multiple sclerosis in a small

Dr Reddy's: Indian generic Rituxan launch flashes warning to ...  -  May 2, 2007
Pharmaceutical Business ReviewDr Reddy's has launched a generic version of Genentech/Biogen Idec/Roche's monoclonal antibody, Rituxan, in India. With plans to market 'Reditux' in other

Avonex, Rituxan and Tysabri boost Biogen Idec revenues  -  May 3, 2007
Pharma Times (subscription),Revenues from the rheumatoid arthritis and cancer drug Rituxan (rituximab), which come from Biogen's joint venture with Genentech, rose 13% to $207 million.

Genentech, Biogen Release Rituxan Data  -  May 1, 2007
Forbes,Biotechnology companies Genentech Inc. and Biogen Idec Inc. said Tuesday additional data from a midstage study of Rituxan for multiple sclerosis showed it

Lupus cured by accident?  -  May 15, 2007
The Grand Rapids Press,Rituxan made news recently when former Tennessee Sen. Fred Thompson, an actor and Republican politician considering a bid for president,

Slow reaction  -  May 16, 2007
South Bend Tribune,Taber says the current standard is to treat the first occurrence with Rituxan, itself a revolutionary drug, along with conventional chemotherapy and

Analysis: Biogen sees rise in key drugs  -  May 2, 2007
United Press InternationalBiogen together with Genentech Tuesday released phase 2 data at the American Academy of Neurology meeting showing Rituxan may be just as efficacious as

Biogen Idec Reports First Quarter 2007 Results  -  May 2, 2007
Business Wire (press release),Revenues for the first quarter 2007 included $207 million from Biogen Idec’s joint business arrangement related to RITUXAN, a treatment for certain B-cell

'Smart bomb' drugs for lymphoma underused  -  May 5, 2007
North County Times,A closely watched government trial is trying to prove that, by comparing Bexxar plus standard chemotherapy to Rituxan plus chemo in about 500 newly

Smart bombs for lymphoma underused  -  May 4, 2007
Napa Valley Register,The leading treatment is Genentech and Biogen Idec’s blockbuster seller Rituxan, a stand-alone antibody — no drug attached — that by itself kills cancer

Biogen's Measured Growth  -  May 2, 2007
Motley FoolRevenue for the quarter was up 17% as sales of the two compounds that comprise the vast majority of Biogen's revenue, Avonex and Rituxan, both experienced

'Smart-bomb' drugs underused by lymphoma patients  -  May 2, 2007
Kentucky.com,The leading treatment is Biogen Idec's blockbuster seller Rituxan, a stand-alone antibody -- no drug attached -- that by itself kills cancer cells,

Lymphoma Drug Failure Frustrates Experts  -  Apr 30, 2007
San Francisco Chronicle,The leading treatment is Genentech and Biogen Idec's blockbuster seller Rituxan, a stand-alone antibody — no drug attached — that by itself kills cancer

Lymphoma Drug Failure Frustrates Experts  -  Apr 30, 2007
CBS News,The leading treatment is Biogen Idec's blockbuster seller Rituxan, a stand-alone antibody _ no drug attached _ that by itself kills cancer cells,

Healthbeat: Smart bombs for lymphoma underused  -  Apr 30, 2007
San Diego Union Tribune,The leading treatment is Biogen Idec's blockbuster seller Rituxan, a stand-alone antibody – no drug attached – that by itself kills cancer cells,

Smart bombs for lymphoma underused  -  Apr 30, 2007
Salt Lake Tribune,The leading treatment is Biogen Idec's blockbuster seller Rituxan, a stand-alone antibody - no drug attached - that by itself kills cancer cells,

Lymphoma drug failure frustrates experts  -  May 1, 2007
CTV.ca,The leading treatment is Genentech and Biogen Idec's blockbuster seller Rituxan, a stand-alone antibody -- no drug attached -- that by itself kills cancer

Royalty Pharma and InNexus Biotechnology Announce Agreement ...  -  26 Apr 2007
Genetic Engineering News (press release),Amgen's Neupogen(R) and Neulasta(R), Genentech's Rituxan(R), Gilead's Emtriva(R), Truvada(R) and Atripla(R), and Celgene's Thalomid(R).

Royalty Pharma and InNexus Biotechnology Announce Agreement ...  -  26 Apr 2007
Business Wire (press release),...including Abbott’s Humira®, Amgen’s Neupogen® and Neulasta®, Genentech’s Rituxan®, Gilead’s Emtriva®, Truvada® and Atripla®, and Celgene’s Thalomid®.

90 Minute Infusion of Rituxan® Well Tolerated  -  Apr 16, 2007
Cancer Consultants (press release),Researchers from Canada have reported that a 90 minute infusion of Rituxan (rituximab) is safe with resultant decrease in time and resource utilization.

Immune 'Killer Cells' Increase Antibody Effectiveness Against Cancer  -  Apr 24, 2007
eMaxHealth.com,The researchers also found that the monoclonal antibody Rituxan greatly enhanced the cancer cell-killing ability of the expanded NK cells against another

Roche Posts Strong First Quarter Sales – Upgrade of Core Earnings ...  -  Apr 18, 2007
PharmaLive.com (press release),MabThera/Rituxan for non-Hodgkin’s lymphoma (NHL) delivered strong sales growth of 17%. Sales increased in all major regions, and in particular emerging

Novel method to expand the number of immune system "natural killer ...  -  Apr 20, 2007
News-Medical.net,The researchers also found that the monoclonal antibody Rituxan greatly enhanced the cancer cell-killing ability of the expanded NK cells against another

Analysis: Genentech's Q1 disappoints  -  Apr 12, 2007
United Press InternationalTotal product sales hit $2.3 billion, which was in line with consensus, but US sales of Lucentis, Rituxan and Herceptin fell short of expectations.

Lawrence McQuillan and Hovannes Abramyan: Tort system has consequences  -  Apr 17, 2007
Examiner.comBut new methods of chemotherapy in addition to drugs, such as Rituxan, changed all that. One study found that a combination of the two treatments improved

Genentech Q1 2007 Earnings Call Transcript  -  Apr 11, 2007
Seeking Alpha,Now to Rituxan. Rituxan net US sales reached $535 million, a 12% increase over Q1 2006. Rituxan's overall adoption rate in NHL and CLL, including the use of

Multiple sclerosis: novel therapies set to increase market value  -  Apr 17, 2007
Pharmaceutical Business ReviewIf Rituxan and MBP-8298 launch, then strong uptake can be expected and seven major market sales are forecasted to reach $633 million and $479 million in

Actor/politician in remission, feeling good, thinking of running ...  -  Apr 13, 2007
ChronicleHerald.ca,But then doctors noticed growth of additional lymph nodes and gave him Rituxan, the first in a new generation of drugs that over the last decade has

Fred Thompson discloses past cancer diagnosis  -  Apr 11, 2007
Los Angeles Times,After being diagnosed, Thompson received Rituxan, the first in a new generation of drugs that over the last decade has revolutionized lymphoma care.

Genentech Q1 Profit, Revenue Top Consensus; Sees FY07 EPS Growth ...  -  Apr 11, 2007
Trading Markets,Rituxan used in the treatment for non-Hodgkin's lymphoma and rheumatoid arthritis, garnered revenues of $535 million, reflecting a growth of 12% over the

EARNINGS OUTLOOK Genentech sales seen rising 38% over last year  -  Apr 9, 2007
MarketWatchHe believes that "flattish" quarters from two of Genentech's three top cancer treatments -- Rituxan, used to treat relapsed or refractory non-Hodgkin's

Pipeline Insight: Disease Modification in Rheumatoid Arthritis ...  -  Apr 18, 2007
Pharmaceutical Business Review...to launch a CD20-inhibiting monoclonal antibody to follow, and build upon, the success shown by Rituxan/MabThera (rituximab) in the RA indication.

Genentech financially strong while Amgen struggles  -  Apr 13, 2007
BiopharmaReporter.com,Genentech said strong sales of cancer drugs Avastin and Rituxan (Rituximab) were the main growth drivers in the quarter results.

Genentech 1Q Profit Up 68 Pct. to $706M  -  Apr 12, 2007
Durham Herald Sun,Sales of the company's drug Rituxan, which treats rheumatoid arthritis and non-Hodgkin's lymphoma, rose 12 percent to $535 million in the first quarter

Ahead of the Bell: Genentech  -  Apr 12, 2007
Houston Chronicle,Net income rose 68 percent, to $706 million from $421 million, due to better sales of cancer drugs, including Avastin and Rituxan.

New Drugs Deliver for Genentech  -  Apr 12, 2007
Smartmoney.comBut sales of Rituxan, used to treat relapsed or refractory non-Hodgkin's lymphoma, came in at $535 million vs. $560 million in the fourth quarter and $477

Market Report -- Story Stocks (DNA)  -  Apr 12, 2007
MSN MoneyWhile Genentech is less of a growth story, the company still has numerous blockbusters like Avastin, Herceptin, and Rituxan to its name,

Making specialty drugs cheaper  -  Mar 31, 2007
Marketplace,His oncologist suggested traditional chemotherapy as well as a specialty drug called Rituxan. Baker was all for it. Rituxan is produced by his colleagues at

Genentech Net Rises 68% on Sales of Cancer Drugs (Update4)  -  Apr 11, 2007
BloombergApril 11 (Bloomberg) -- Genentech Inc. said first-quarter profit rose 68 percent, driven by sales of its cancer drugs Avastin and Rituxan and revenue from

Realtors predict fewer housing sales in 2007  -  Apr 11, 2007
San Jose Mercury News,Genentech is benefiting from increased sales of cancer drugs Avastin and Rituxan. In the three months that ended March 31, Avastin sales were up 34 percent

Genentech profits surge  -  Apr 12, 2007
San Mateo County Times,Rituxan, which is used to treat non-Hodgkin's lymphoma, continues to be the company's top seller, but Avastin, used to treat colorectal and lungcancer,

Genentech Net Rises 68% on Sales of Cancer Drugs (Update1)  -  Apr 11, 2007
BloombergApril 11 (Bloomberg) -- Genentech Inc. said first-quarter profit rose 68 percent, driven by sales of its cancer drugs Avastin and Rituxan.

Genentech 1Q profit up 68 pct. to $706M  -  Apr 11, 2007
The Westfall Weekly News,Sales of the company‘s drug Rituxan, which treats rheumatoid arthritis and non-Hodgkin‘s lymphoma, rose 12 percent to $535 million in the first quarter

Genentech Sales Forecast to Rise  -  Apr 9, 2007
Wall Street Journal (subscription),Rodman & Renshaw analyst Michael King believes Genentech was basing its outlook on "flattish" quarters from some of its drugs, including Rituxan,

Charity calls for more health-worker aid  -  Apr 13, 2007
United Press International...but analysts were disappointed with the performances of the biotech giant's key products, including Avastin, Rituxan and Lucentis. By TODD ZWILLICH

Genentech Gets Its Lab Work Back: Fool by Numbers  -  Apr 12, 2007
Motley FoolBIIB) submitted a supplemental Biologics License Application to the FDA to include treatment active rheumatoid arthritis by existing product Rituxan.

Genentech profit surges 68 percent in 1st quarter  -  Apr 12, 2007
San Jose Mercury News,...profit surge of 68 percent over the same period last year behind continued strong sales of its stable of blockbuster cancer drugs, Avastin and Rituxan.

Genentech Earnings Pop 68% On Strong Overseas Sales  -  Apr 11, 2007
Forbes,Sales of Rituxan, a non-Hodgkins lymphoma treatment, jumped 12% to $535 million, but analysts were expecting it to sell more briskly.

Genentech 1Q earnings driven by robust cancer drug sales  -  Apr 12, 2007
newratings.comThe US sales of Rituxan, a treatment for non Hodgkins’ lymphoma rose 12% to $535 million in the latest quarter, while sales of the company’s lung cancer

Genentech Profit Increases 68%  -  Apr 11, 2007
New York Times,Genentech said yesterday that first-quarter profit rose 68 percent, driven by sales of its cancer drugs Avastin and Rituxan.

Genentech Reports a Profit Surge  -  Apr 12, 2007
Schaeffers Research,On the other hand, sales of Rituxan, used to treat relapsed or refractory non-Hodgkin's lymphoma, came in at $535 million, compared to $560 million in the

Genentech Beats on Bottom Line  -  Apr 11, 2007
TheStreet.comThe lymphoma drug Rituxan's 12% sales increase to $535 million also left it short of Wall Street's target. Looking ahead, Genentech repeated its earlier

Thompson cancer disclosure tests water  -  Apr 12, 2007
Robertson County Times,He said Thompson took the cancer drug Rituxan but is no longer undergoing therapy. "Some lymphomas are aggressive, but people with slow-growing types,

Realtors expect median existing home price to drop this year ...  -  Apr 11, 2007
Austin American-Statesman (subscription),SAN FRANCISCO — Genentech Inc. said its first-quarter profit rose 68 percent, driven by sales of its cancer drugs Avastin and Rituxan and revenue from

Genentech profit grows in Q1  -  Apr 11, 2007
MSN MoneyUS sales of Genentech's cancer drug Avastin grew 34 percent compared with a year ago, and sales of Rituxan in the United States also grew 12 percent.

Tennessee GOP head: Cancer admission shows Thompson's honesty  -  Apr 11, 2007
Fairview Observer,Senator Thompson chose to receive such therapy (Rituxan), but he is no longer in treatment as he is in remission.

Former Senator Fred Thompson in Remission for Lymphoma  -  Apr 11, 2007
MyFox Washington DC,Thompson had been on a cancer therapy called Rituxan, but is not currently in treatment. "Some lymphomas are very aggressive, but people with slow-growing

This site is for informational purposes only--it does not offer medical advice or sell health products. If you need assistance, contact your physician or healthcare professional